Patents Examined by John S Kenyon
  • Patent number: 11912662
    Abstract: A 2-alkoxy[4,3:6,2-terpyridine]-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: February 27, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11917912
    Abstract: An organic compound is represented by general formula [1-1]. In general formula [1-1], X is an oxygen atom, a sulfur atom, a selenium atom, or a tellurium atom, and R1 to R18 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted silyl group, and a cyano group.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: February 27, 2024
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yosuke Nishide, Jun Kamatani, Naoki Yamada, Hironobu Iwawaki, Hirokazu Miyashita
  • Patent number: 11905260
    Abstract: A N?-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11905262
    Abstract: N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11897893
    Abstract: Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: February 13, 2024
    Assignee: University of Maryland, College Park
    Inventors: Lyle David Isaacs, Volker Briken, Gaya Hettiarachchi, Da Ma, Duc M. Nguyen
  • Patent number: 11897860
    Abstract: A method for direct synthesis of cyclic carbonates is achieved by reacting at least one epoxide with carbon dioxide in the presence of a choline catalyst, such as choline chloride, under mild conditions such as a temperature between about 25° C. to 150° C. and a pressure of from about atmospheric to 75 psi (0.52 MPa), in a cyclic carbonate solvent. The choline catalyst may be the only catalyst used, and a co-catalyst or hydrogen bond donor is not necessary. The concentration of choline catalyst in the solvent ranges from about 0.5 mol % to about 10 mol %, based on the epoxide.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: February 13, 2024
    Assignee: Baker Hughes Oilfield Operations LLC
    Inventors: Analette Carrasco, Jerry J. Weers, Catherine C Blackwell, Sankaran Murugesan, Xiaofeng Wang, Douglas Nugent, Corby A. Roberts
  • Patent number: 11891402
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: February 6, 2024
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Patent number: 11890262
    Abstract: A composition and method for treatment of brittle, broken, cracked or otherwise damaged nail and hoof plates. The composition is an aqueous-organic medium containing a non-covalent complex of a diamine and an organic acid or an aqueous-organic medium with a diamine alone.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 6, 2024
    Assignee: WELLA OPERATIONS US, LLC
    Inventors: Elizabeta Pavlovic, Sunan Yuvavanich
  • Patent number: 11884613
    Abstract: The invention relates to processes for preparing carbaprostacyclin analogues and intermediates prepared from the processes. The invention also relates to cyclopentenone intermediates in racemic or optically active form.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: January 30, 2024
    Assignee: CHIROGATE INTERNATIONAL INC.
    Inventors: Chun-Yu Lin, Tzyh-Mann Wei, Shih-Yi Wei
  • Patent number: 11878022
    Abstract: Disclosed herein is a powder for oral suspension and a reconstituted product thereof comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: January 23, 2024
    Assignee: Novitium Pharma LLC
    Inventors: Muthusamy Shanmugam, Subramaniam Arunkumar
  • Patent number: 11878008
    Abstract: Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 23, 2024
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Gyeyoung Choi, Hyunjin Nam, Miyoung Park, Kyoungmi Jung, Jihae Lee, Chang Soon Choi, Youngho Park, Jong Hwa Roh, Eunsil Park, Jaehong Park, Kwanghyun Shin, Byoung Young Woo, Kiwha Lee, Wonkyung Cho, Joonho Choi
  • Patent number: 11878000
    Abstract: The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.
    Type: Grant
    Filed: October 21, 2017
    Date of Patent: January 23, 2024
    Assignees: Da Zen Theranostics, Inc., Cedars-Sinai Medical Center
    Inventors: Liyuan Yin, Yi Zhang, Stefan Mrdenovic, Gina Chia Yi Chu, Ruoxiang Wang, Qinghua Zhou, Jian Zhang, Leland W. K. Chung
  • Patent number: 11872224
    Abstract: The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: January 16, 2024
    Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co. (Beijing), Ltd.
    Inventors: Chi-Feng Yen, Fang-Wei Tien
  • Patent number: 11873432
    Abstract: Luminescent materials that include a luminescent phosphor compound, articles including a security feature, and methods for producing the luminescent phosphor compounds are provided herein. In an embodiment, a luminescent material includes a medium and luminescent particles. The luminescent particles include a luminescent benzothiazole having a ureido linkage. The luminescent benzothiazole has a peak intensity within a wavelength of from about 555 to about 630 nm in response to excitation with electromagnetic radiation at a wavelength of about 366 nm.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 16, 2024
    Assignee: HONEYWELL INTERNATIONAL INC.
    Inventors: Thomas Potrawa, Michael Kessler
  • Patent number: 11865112
    Abstract: Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: January 9, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Haiyong Hugh Huang, Manjunath S. Shet
  • Patent number: 11866439
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: January 9, 2024
    Assignee: PRAXIS PRECISION MEDICINES, INC.
    Inventors: Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy, Marion Wittmann
  • Patent number: 11864567
    Abstract: The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: January 9, 2024
    Assignee: ELANCO US INC.
    Inventors: Cory T. Herr, John Charles Kube, Jerold Scott Teeter
  • Patent number: 11866450
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: January 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Patent number: 11857547
    Abstract: Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: January 2, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Haiyong Hugh Huang, Manjunath S. Shet
  • Patent number: 11850231
    Abstract: The present invention is a natural anthropogenic dietary supplement containing tryptophan in combination with vitamins as well as minerals in order to facilitate treatment of sleep disorders such as but not limited to jet lag disorder and circadian rhythm sleep disorder. The composition of the present invention facilitates increased metabolism of tryptophan. The compositions of the present invention are provided in either gel capsules or as a beverage dose for consumption. The compositions of the present invention include embodiments that incorporate as a part thereof calcium salts and magnesium salts. Vitamins such as but not limited to niacin are further included in embodiments of the composition of the present invention. Furthermore, additional natural ingredients further contribute to the makeup of the embodiments of the composition of the present invention.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: December 26, 2023
    Inventor: Christina Rahm Cook